Overexpression of ZFX confers self‐renewal and chemoresistance properties in hepatocellular carcinoma. Issue 8 (11th March 2014)

• Record Type: Journal Article
• Authors: Lai, Keng Po; Chen, Jiawei; He, Mian; Ching, Arthur K.K.; Lau, Coleen; Lai, Paul B.S.; To, Ka‐Fai; Wong, Nathalie
• Is Part Of: International journal of cancer. Volume 135:Issue 8(2014:Oct. 15)
• Page Start: 1790
• Page End: 1799
• Publication Date: 2014-03-11
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.28819
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Zinc finger protein X‐linked (ZFX) is a zinc finger protein of Zfy family, which is highly conserved in vertebrates. This transcriptional regulator is not only highly expressed in embryonic stem cells (ESC) and hematopoietic stem cells, but is also upregulated in a number of human cancers where it is functional related to cell proliferation and survival. Hepatocellular carcinoma (HCC) is highly aggressive cancer that commonly resistant to most chemotherapies and displays stemness characteristics. In this study, we examined the expression of ZFX in HCC and its possible functional implications in liver tumorigenesis. Quantitative RT‐PCR analysis showed common overexpressions of ZFX in 51.8% HCC tumors when compared with their adjacent nonmalignant liver (<italic>n</italic> = 43/83; <italic>p</italic> = 0.004). Inline with the pluripotency role of ZFX, we found silencing of ZFX readily inhibited self‐renewal capability (<italic>p</italic> = 0.0022), colony formation ability (<italic>p</italic> < 0.0001) and cell proliferation (<italic>p</italic> < 0.0001) through G0/G1 cell cycle arrest of HCC cells (<italic>p</italic> = 0.0038). In addition, suppression of ZFX sensitized HCC cells to chemotherapeutic agent cisplatin (<italic>p</italic> < 0.0001). Further investigations suggested that ZFX bind on the promoter of two important mediators, namely Nanog and SOX‐2, activating their expressions in HCC (<italic>p</italic> < 0.0001). Moreover, <italic>in vivo</italic> xenograft study demonstrated that overexpression of ZFX would promote the tumor growth (<italic>p</italic> = 0.031). Taken together, our results show, for the first time, commonly overexpressions of ZFX in HCC, where it likely contributes to the stemness and pluripotent behavior of this highly malignant cancer.</p> </abstract>